论文部分内容阅读
于1995年2月至1997年8月我们选择12例进入完全缓解期的急性白血病患者进行大剂量化疗，旨在探讨该疗法在基层医院的可行性。本组急性淋巴细胞性白血病（ALL）9例，急性非淋巴细胞性白血病（ANLL）3例，分别用大剂量氨甲喋吟和阿糖胞苷等，其剂量均在1-3g／M2之间。对于ALL患者在给予大剂量开始后2小时内同时给予“三联”鞘注一次，并同步给予VP方案，均连续3个疗程。结果：骨髓象呈不同程度的抑制，但多不严重。白细胞，血小板于1一2周升至正常，其它检查无明显异常。本组未出现严重感染及大出血者，也未出现因毒副作用而中止化疗者。认为大剂量化疗在具有一定条件的基层医院是可以推广应用的。
From February 1995 to August 1997, we selected 12 patients with acute leukemia who had undergone complete remission to undergo high-dose chemotherapy to explore the feasibility of this therapy in primary hospitals. The group of acute lymphoblastic leukemia (ALL) in 9 cases, acute non-lymphocytic leukemia (ANLL) in 3 cases, respectively, with high-dose of methotrexate and cytarabine dose of 1-3g / M2 between. For patients with ALL in the first two hours after the start of high dose given “triple ” intrathecal injection, and simultaneously given VP regimen, were 3 consecutive courses. Results: Different degrees of bone marrow suppression, but not serious. White blood cells, platelets rose to normal in 1 to 2 weeks, other tests no obvious abnormalities. This group did not appear serious infection and bleeding, nor because of the side effects of chemotherapy stopped. That the high-dose chemotherapy in the grass-roots hospitals have certain conditions is to promote the use of.